Astec LifeSciences Limited Announces Unaudited Standalone and Consolidated Earnings Results for Second Quarter and Half Year Ended September 30, 2017
October 25, 2017 at 07:38 am EDT
Share
Astec LifeSciences Limited announced unaudited standalone and consolidated earnings results for second quarter and half year ended September 30, 2017. For the quarter, the company reported standalone revenues from operations were INR 959.288 million against revenues from operations of INR 897.341 million a year ago. Profit before exceptional items and tax was INR 100.6 million against profit before exceptional items and tax of INR 165.228 million a year ago. Profit before tax was INR 100.6 million against profit before tax of INR 149.324 million a year ago. Net profit was INR 67.014 million against net profit of INR 111.626 million a year ago. Basic and diluted per share was INR 3.43 against basic and diluted per share of INR 5.71 a year ago.
For the period, the company reported standalone revenues from operations were INR 1,681.993 million against revenues from operations of INR 1,599.209 million a year ago. Profit before exceptional items and tax was INR 160.256 million against profit before exceptional items and tax of INR 216.137 million a year ago. Profit before tax was INR 160.256 million against profit before tax of INR 200.233 million a year ago. Net profit was INR 106.905 million against net profit of INR 149.014 million a year ago. Basic and diluted per share was INR 5.46 against basic and diluted per share of INR 7.63 a year ago.
For the quarter, the company reported consolidated revenues from operations were INR 959.289 million against revenues from operations of INR 903.292 million a year ago. Profit before exceptional items and tax was INR 100.811 million against profit before exceptional items and tax of INR 166.233 million a year ago. Profit before tax was INR 100.811 million against profit before tax of INR 150.329 million a year ago. Net profit was INR 67.151 million against net profit of INR 112.53 million a year ago. Basic and diluted per share was INR 3.43 against basic and diluted per share of INR 5.73 a year ago.
For the period, the company reported consolidated revenues from operations were INR 1,681.994 million against revenues from operations of INR 1,605.16 million a year ago. Profit before exceptional items and tax was INR 160.519 million against profit before exceptional items and tax of INR 217.383 million a year ago. Profit before tax was INR 160.519 million against profit before tax of INR 201.479 million a year ago. Net profit was INR 107.02 million against net profit of INR 150.084 million a year ago. Basic and diluted per share was INR 5.41 against basic and diluted per share of INR 7.66 a year ago.
Astec LifeSciences Limited is an India-based company that is primarily engaged in manufacturing a range of agrochemical active ingredients and pharmaceutical intermediates. The Company operates through the Agrochemicals segment. It manufactures a range of fungicides, insecticides, herbicides, and intermediates for its global customers. The Companyâs products and intermediates includes triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, silane derivatives, fluorinated aromatic, aliphatic and heterocyclic intermediates, fluorinated aromatic amines, fluorinated pyridine derivatives, fluorinated aromatic carboxylic acids, fluorinated benzyl alcohols, fluorinated ketones and benzophenones, fluorinated heterocyclic mercaptans, heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, thorium salts, pyrazaloneâs and heterocyclic sulfonyl chlorides.
ASTEC LIFESCIENCES LIMITED 
